Central disinhibition is a mechanism involved in the physiopathology of fibromyalgia. Melatonin can improve sleep quality, pain and pain threshold. We hypothesized that treatment with melatonin alone or in combination with amitriptyline would be superior to amitriptyline alone in modifying the endogenous pain-modulating system (PMS) as quantified by conditional pain modulation (CPM), and this change in CPM could be associated with serum brain-derived neurotrophic factor (BDNF). We also tested whether melatonin improves the clinical symptoms of pain, pain threshold and sleep quality.
Background: Fibromyalgia (FM) is conceptualized as a central sensitization (CS) condition, that presents high serum brain-derived neurotrophic factor (BDNF) and neuroglia activation. Although the S100B protein regulates neuroglia functions, it has been traditionally used as a proxy of central nervous system damage. However, neither BDNF nor S100B association with the clinical picture of FM has been elucidated. To explore their association with the pressure-pain threshold (PPT) in FM, we performed a cross-sectional study, including 56 females with confirmed FM aged 18–65 years. Linear regression models were used to adjust for potential confounding factors between serum BDNF, S100B and PPT. Results: Serum BDNF and S100B were correlated (Spearman's Rho = 0.29). Serum BDNF ( log) and S100B ( log) were correlated with the PPT ( log) (Partial η2 = 0.129, P = 0.012 for the BDNF ( log), and Partial η2 = 0.105, P = 0.025 for the S100B ( log)). Serum BDNF ( log) was inversely associated with PPT ( log) (β = −1.01, SE = 0.41), age (β = −0.02, SE = 0.15) and obsessive compulsive disorder (β = −0.36, SE = 0.15), while serum S100B ( log) was inversely associated with PPT ( log) (β = −1.38, SE = 0.50), only. Conclusions: Both neuroglia key mediators in the CS process were inversely correlated with the PPT. Serum assessment of BDNF and S100B deserve further study to determine its potential as a proxy for the CS spectrum in FM.
This study aimed to answer three questions related to chronic myofascial pain syndrome (MPS): 1) Is the motor cortex excitability, as assessed by transcranial magnetic stimulation parameters (TMS), related to state-trait anxiety? 2) Does anxiety modulate corticospinal excitability changes after evoked pain by Quantitative Sensory Testing (QST)? 3) Does the state-trait anxiety predict the response to pain evoked by QST if simultaneously receiving a heterotopic stimulus [Conditional Pain Modulation (CPM)]? We included females with chronic MPS (n = 47) and healthy controls (n = 11), aged 19 to 65 years. Motor cortex excitability was assessed by TMS, and anxiety was assessed based on the State-Trait Anxiety Inventory. The disability related to pain (DRP) was assessed by the Profile of Chronic Pain scale for the Brazilian population (B:PCP:S), and the psychophysical pain measurements were measured by the QST and CPM.
7 May 2015 in BMC Complementary and Alternative Medicine
Chronic tension-type headache (CTTH) is characterized by almost daily headaches and central sensitization, for which electroacupuncture (EA) might be effective. The central nervous system (CNS) plasticity can be tracked in serum using the brain-derived neurotrophic factor (BDNF), a neuroplasticity mediator. Thus, we tested the hypothesis that EA analgesia in CTTH is related to neuroplasticity indexed by serum BDNF. We enrolled females aged 18–60 years with CTTH in a randomized, blinded, placebo-controlled crossover trial, comparing ten EA sessions applied for 30 minutes (2–10 Hz, intensity by tolerance) in cervical areas twice per week vs. a sham intervention. Treatment periods were separated by two washout weeks. Pain on the 10-cm visual analog scale (VAS) and serum BDNF were assessed as primary outcomes. Thirty-four subjects underwent randomization, and twenty-nine completed the protocol. EA was superior to sham to alleviate pain (VAS scores 2.38 ± 1.77 and 3.02 ± 2.49, respectively, P = 0.005). The VAS scores differed according to the intervention sequence, demonstrating a carryover effect (P < 0.05). Using multiple regression, serum BDNF was adjusted for the Hamilton depression rating scale (HDRS) and the VAS scores (r-squared = 0.07, standard β coefficients = −0.2 and −0.14, respectively, P < 0.001). At the end of the first intervention period, the adjusted BDNF was higher in the EA phase (29.31 ± 3.24, 27.53 ± 2.94 ng/mL, Cohen’s d = 0.55). EA analgesia is related to neuroplasticity indexed by the adjusted BDNF. EA modulation of pain and BDNF occurs according to the CNS situation at the moment of its administration, as it was related to depression and the timing of its administration.
31 March 2015 in Frontiers in Behavioral Neuroscience
Transcranial direct current stimulation (tDCS) and melatonin can effectively treat pain. Given their potentially complementary mechanisms of action, their combination could have a synergistic effect. Thus, we tested the hypothesis that compared to the control condition and melatonin alone, tDCS combined with melatonin would have a greater effect on pain modulatory effect, as assessed by quantitative sensory testing (QST) and by the pain level during the Conditional Pain Modulation (CPM)-task. Furthermore, the combined treatment would have a greater cortical excitability effect as indicated by the transcranial magnetic stimulation (TMS) and on the serum BDNF level. Healthy males (n=20), (aged 18 to 40 years), in a blinded, placebo-controlled, crossover, clinical trial, were randomized into three groups: sublingual melatonin (0.25 mg/kg)+ a-tDCS, melatonin (0.25 mg/kg)+sham-(s)-tDCS, or sublingual placebo+s-tDCS. Anodal stimulation (2 mA, 20 min) was applied over the primary motor cortex. There was a significant difference in the heat pain threshold (°C) for melatonin+a-tDCS vs. placebo+s-tDCS (mean difference: 4.86, 95% confidence interval [CI]: 0.9 to 8.63) and melatonin+s-tDCS vs. placebo+s-tDCS (mean: 5.16, 95% CI: 0.84 to 8.36). There was no difference between melatonin+s-tDCS and melatonin+a-tDCS (mean difference: 0.29, 95% CI: −3.72 to 4.23). The mean change from the baseline on amplitude of motor evocate potential (MEP) was significantly higher in the melatonin+a-tDCS (−19.96%±5.2) compared with melatonin+s-tDCS group (−1.36%±5.35) and with placebo+s-tDCS group (3.61%±10.48), respectively (P<0.05 for both comparisons). While melatonin alone or combined with a-tDCS did not significantly affect CPM task result, and serum BDNF level. The melatonin effectively reduced pain; however, its association with a-tDCS did not present an additional modulatory effect on acute induced pain.
O objetivo deste estudo foi avaliar o estoque domiciliar de medicamentos em comunidades atendidas pela Estratégia de Saúde da Família (ESF) em município localizado no Sul do Brasil. Foram amostrados 10% dos domicílios de cinco ESF. Os dados foram coletados por Agentes Comunitários de Saúde (ACS) através de questionário adaptado. A idade média dos entrevistados foi de 42 anos e dos moradores foi de 16 anos, destes 51% eram mulheres. Foi observada renda de 1 a 3 salários mínimos (69,1%), e escolaridade de 0 a 4 anos de estudo (42%). Dos domicílios visitados, 98,7% apresentavam pelo menos um medicamento estocado. Dos 533 lugares de guarda averiguados, 43,5% estava exposto ao calor, 39,6% a umidade, 16,5% a luz. Dos 2.717 medicamentos encontrados, 6,9% estavam vencidos, 35,3% não estavam dentro da embalagem secundária, quando esta se aplica, 67,9% não continham a presença de bula. Os fármacos analgésicos foram os mais prevalentes no estoque (21%). Os resultados nos levam a concluir que há necessidade de equipe multiprofissional para a promoção de saúde e a racionalização dos estoques domiciliares de medicamentos, sendo que o ACS é um profissional indispensável para a promoção do uso racional de medicamentos.